Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q01954
UPID:
BNC1_HUMAN
Alternative names:
-
Alternative UPACC:
Q01954; Q15840
Background:
Zinc finger protein basonuclin-1 plays a pivotal role in various biological processes, including keratinocytes terminal differentiation and hair follicle development. It is essential for spermatogenesis and positively regulates oocyte maturation through BMP15 levels and AKT signaling cascade modulation. Additionally, it contributes to early embryo development.
Therapeutic significance:
Linked to Premature ovarian failure 16, a condition characterized by early cessation of ovarian function, understanding the role of Zinc finger protein basonuclin-1 could open doors to potential therapeutic strategies.